Novel approaches with targeted therapies in bladder cancer: Therapy of bladder cancer by blockade of the epidermal growth factor receptor family

Keyphrases

• Advanced Disease 20%
• Angiogenesis 20%
• Anti-HER2 Antibody 20%
• Apoptosis 20%
• Athymic nude Mice 20%
• Biological Agents 20%
• Bladder Cancer 100%
• Bladder Cancer Model 20%
• Bladder Cancer Therapy 100%
• Bladder Wall 20%
• C225 20%
• Cancer Patients 20%
• Cancer Progression 20%
• Cetuximab 20%
• Chemotherapy 20%
• Combined Modality Therapy 20%
• Cytoreductive Surgery 20%
• Egfr 20%
• EGFR Inhibitors 20%
• EGFR-targeting 20%
• Epidermal Growth Factor 20%
• Epidermal Growth Factor Receptor 20%
• Epidermal Growth Factor Receptor Family 100%
• ErbB1 20%
• ErbB2 20%
• Growth Factor Inhibitors 20%
• Growth Factors 20%
• Growth Hormone Receptor 60%
• Her2neu 40%
• Herceptin 20%
• Human Tumors 20%
• Iressa 20%
• Metastasis 20%
• Molecular Biology 20%
• Multiple Aspects 20%
• New Agents 20%
• New Biologics 20%
• New Targets 20%
• Novel Targeted Therapy 20%
• Poor Prognosis 20%
• Prognostic Score 20%
• Systemic Administration 20%
• Tarceva 20%
• Targeted Agents 40%
• Targeted Therapy 100%
• Therapeutic Target 20%
• Transitional Cell Carcinoma 20%
• Treatment Choice 20%
• Tumor Cell Proliferation 20%
• Tumor Subtype 20%
• Tyrosine Kinase Receptor 20%
• Urothelial Malignancy 20%
• Urothelial Tumors 20%
• Vascular Endothelial Growth Factor 20%

Medicine and Dentistry

• Angiogenesis 12%
• Antiinfective Agent 12%
• Biological Product 12%
• Bladder Cancer 100%
• Bladder Wall 12%
• Cancer 12%
• Cancer Growth 12%
• Cancer Model 12%
• Cancer Therapy 100%
• Cell Proliferation 12%
• Cetuximab 25%
• Chemotherapy 12%
• Diseases 12%
• EGFR Inhibitors 12%
• Epidermal Growth Factor 12%
• Epidermal Growth Factor Receptor 100%
• ErbB 12%
• Erlotinib 12%
• Gefitinib 12%
• Growth Factor 25%
• Growth Factor Receptor 37%
• Malignant Neoplasm 12%
• Metastatic Carcinoma 12%
• Monoclonal Antibody 12%
• Neoplasm 25%
• Programmed Cell Death 12%
• Receptor 25%
• Receptor Family 100%
• Systemic Administration 12%
• Targeted Therapy 100%
• Transitional Cell Carcinoma 12%
• Trastuzumab 12%
• Tumor Cell 12%
• Tyrosine Kinase Receptor 12%
• Urogenital Tract Tumor 12%
• Vasculotropin 12%

Pharmacology, Toxicology and Pharmaceutical Science

• Antiinfective Agent 12%
• Biological Product 12%
• Bladder Cancer 100%
• Cancer Growth 12%
• Cancer Model 12%
• Cetuximab 25%
• Chemotherapy 12%
• Disease 12%
• Epidermal Growth Factor 12%
• Epidermal Growth Factor Receptor 100%
• Erlotinib 12%
• Gefitinib 12%
• Growth Factor 25%
• Growth Factor Receptor 37%
• Malignant Neoplasm 12%
• Monoclonal Antibody 12%
• Neoplasm 37%
• Nude Mouse 12%
• Preclinical Study 12%
• Receptor 25%
• Systemic Administration 12%
• Transitional Cell Carcinoma 12%
• Trastuzumab 12%
• Tyrosine Kinase Receptor 12%
• Urogenital Tract Tumor 12%
• Vasculotropin 12%